RxDoctor Payments DataLook up a doctor →

Mohammad Razaq, MD

Hematology & Oncology · Oklahoma City, OKNPI 1710900337

Payments from drug & device makers

$266,517in general payments, 2019–2025

Across 392 payments — averaging $679.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$203K
  • Merck$33K
  • AstraZeneca$6K
  • Bristol Myers Squibb$4K
  • E.r. Squibb & Sons, L.L.C.$4K
  • Incyte Corporation$4K
  • plus $12K from 49 others
$1,485in research payments, 2019–2025

Across 11 payments — averaging $135.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer47$203,497
Merck50$32,530
AstraZeneca(2 entities)48$5,922
Bristol Myers Squibb16$4,254
E.r. Squibb & Sons, L.L.C.25$3,972
Incyte Corporation14$3,874
Takeda Pharmaceuticals U.S.A., Inc.11$2,705
AbbVie5$2,536
Novartis43$2,527
Adaptive Biotechnologies Corporation1$1,200
Daiichi Sankyo Inc.5$613
Regeneron Healthcare Solutions, Inc.8$182
Secura Bio, Inc.1$170
Shield Therapeutics Inc4$156
Astellas Pharma US Inc8$155
Sanofi6$144
Amgen7$140
Johnson & Johnson7$136
Pharmacosmos Therapeutics Inc.1$125
Sobi, Inc4$120
Genentech USA, Inc.6$116
Seagen Inc.6$103
Gilead6$100
Puma Biotechnology, Inc.1$82
Lilly USA, LLC4$80
GSK4$79
ADC Therapeutics America, Inc.4$76
Karyopharm Therapeutics Inc.4$76
Tersera Therapeutics LLC3$75
Pharmacyclics LLC, An Abbvie Company3$64
Acrotech Biopharma Inc.4$54
Phathom Pharmaceuticals, Inc.3$47
Agios Pharmaceuticals, Inc.2$44
Morphosys, US Inc.2$41
EMD Serono, Inc.2$38
Foundation Medicine, Inc.2$37
Aimmune Therapeutics, Inc.2$37
Mirati Therapeutics, Inc.2$37
Taiho Oncology, Inc.2$34
Ipsen Biopharmaceuticals, Inc2$32
Rigel Pharmaceuticals, Inc.2$31
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC2$29
Blueprint Medicines Corporation1$28
Myovant Sciences Inc.1$24
Medtronic1$24
Sun Pharmaceutical Industries Inc.1$23
Beone Medicines USA, Inc.1$23
Stemline Therapeutics Inc.1$17
Alnylam Pharmaceuticals Inc.1$17
Array Biopharma Inc1$16
Ardelyx, Inc.1$15
Pacira Pharmaceuticals Incorporated1$15
Eisai Inc.1$15
CTI Biopharma Corp.1$15
G1 Therapeutics, Inc.1$14

How this compares

$266,517 in reported general payments places this provider in the 85th percentile of 118 hematology & oncology providers in Oklahoma.

See all hematology & oncology providers in Oklahoma →

Medicare billing

Part B allowed, 2024
$193,967
Medicare patients
572
Services billed
2,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Oklahoma City

See the full list for Oklahoma →

Where these figures come from

Is this you, or does something look wrong? →